Int Ophthalmol:急性后玻璃体脱离患者发生多发性视网膜撕裂的危险因素分析

2017-04-07 luowenbo MedSci原创

该研究用于评估急性后玻璃体脱落患者发生多发性视网膜撕裂的可能危险因素。三百七十六名患者持续表现出眼前漂浮物与潮热症状,对眼前漂浮物与潮热症状的持续时间、闪烁、视网膜分离的家族史、外周视网膜退行性变、晶状体状态、近视、烟粉尘、视网膜或玻璃体出血等因素与视网膜撕裂的关系进行探究分析。

该研究用于评估急性后玻璃体脱落患者发生多发性视网膜撕裂的可能危险因素。三百七十六名患者持续表现出眼前漂浮物与潮热症状,对眼前漂浮物与潮热症状的持续时间、闪烁、视网膜分离的家族史、外周视网膜退行性变、晶状体状态、近视、烟粉尘、视网膜或玻璃体出血等因素与视网膜撕裂的关系进行探究分析。

研究结果发现,376名患者中54(14.4%)名发生了视网膜撕裂症状,54眼中有40眼有一处视网膜撕裂症状,而另外14眼中有多处视网膜撕裂症状。单变量分析方法与多变量分析方法发现视网膜或玻璃体出血的存在会将视网膜撕裂的风险增加分别为6.1倍与7.0倍。

急性后玻璃体脱离患者的视网膜撕裂症状若不及时发现并干预,会导致继发性视网膜脱离。因此。对于急性后玻璃体脱离的患者,尤其是存在视网膜或玻璃体出血症状的患者,一定要考虑是否存在多发性视网膜撕裂症状。

原文出处:


本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889737, encodeId=74541889e3711, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 29 02:00:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269861, encodeId=396e1269861f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496200, encodeId=c1b2149620049, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541183, encodeId=262815411836f, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=)]
    2017-11-29 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889737, encodeId=74541889e3711, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 29 02:00:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269861, encodeId=396e1269861f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496200, encodeId=c1b2149620049, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541183, encodeId=262815411836f, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=)]
    2017-04-08 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889737, encodeId=74541889e3711, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 29 02:00:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269861, encodeId=396e1269861f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496200, encodeId=c1b2149620049, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541183, encodeId=262815411836f, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1889737, encodeId=74541889e3711, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 29 02:00:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269861, encodeId=396e1269861f2, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496200, encodeId=c1b2149620049, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541183, encodeId=262815411836f, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Apr 08 15:00:00 CST 2017, time=2017-04-08, status=1, ipAttribution=)]

相关资讯

2015NICE技术评估指南:玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿(TA349)发布

2015年7月22日,英国国家卫生与临床优化研究所 (NICE)发布玻璃体腔内注入地塞米松治疗糖尿病性黄斑水肿的技术评估指南。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Brit J Ophthal:上海九院汪朝阳教授发现玻璃体切割术间使用罗哌卡因疼痛和出血风险更低

为了比较1%罗哌卡因(Ropivacaine), 0.75%布比卡因(Bupivacaine), 2%利多卡因以及0.75%丁哌卡因和2%利多卡因(bupi+lido)的混合制剂在玻璃体切除术球周麻醉的术中和术后临床特性。中国上海交通大学附属第九人民医院汪朝阳教授和新华医院的研究人员开展了一项前瞻性随机双盲临床研究。该研究于2月7日在 British Journal of Ophthal